Absolutely. This is one of the things that we recommended to the committee in the previous Parliament during this exact study: that funding provided for the development of drugs, vaccines, diagnostic tests and other health technologies should be conditional on recipients of public funds having a policy in place which stipulates that if they are going to license it to someone else, it be done in a way that includes provisions that ensure that it will be affordable, accessible and priced fairly when it eventually comes to market. I think that enacting these provisions early upstream gives a degree of control to be able to negotiate some of these provisions fairly effectively.
On June 10th, 2020. See this statement in context.